Seikagaku reported FY 3Q19 orthopedic revenue of ¥3,746.2 million (USD $33.8 million), +10.1% vs. 3Q18. The company’s domestic orthobiologic orders fell slightly despite share gains as the overall Japanese viscosupplement market contracted. Domestic revenue grew in the mid-single digits year over year due primarily to the soft comparison. Seikgaku’s primary growth driver was sales of the Gel-One viscosupplement (+23.1%) in the U.S., where favorable reimbursement decisions and increased marketing efforts helped the company take share. The success of Gel-One came partially at the expense of the company’s SUPARTZ FX five-injection product, as the U.S. market increasingly shifts toward single-injection treatments.
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
3Q19
3Q18
$ Chg
% Chg
Orthobiologics
$33.8
$30.7
$3.1
10.1%
9mo 19
9mo 18
$ Chg
% Chg
Orthobiologics
$107.3
$94.8
$12.5
13.1%
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
Seikagaku reported FY 3Q19 orthopedic revenue of ¥3,746.2 million (USD $33.8 million), +10.1% vs. 3Q18. The company’s domestic orthobiologic orders fell slightly despite share gains as the overall Japanese viscosupplement market contracted. Domestic revenue grew in the mid-single digits year over year due primarily to the soft comparison....
Seikagaku reported FY 3Q19 orthopedic revenue of ¥3,746.2 million (USD $33.8 million), +10.1% vs. 3Q18. The company’s domestic orthobiologic orders fell slightly despite share gains as the overall Japanese viscosupplement market contracted. Domestic revenue grew in the mid-single digits year over year due primarily to the soft comparison. Seikgaku’s primary growth driver was sales of the Gel-One viscosupplement (+23.1%) in the U.S., where favorable reimbursement decisions and increased marketing efforts helped the company take share. The success of Gel-One came partially at the expense of the company’s SUPARTZ FX five-injection product, as the U.S. market increasingly shifts toward single-injection treatments.
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
3Q19
3Q18
$ Chg
% Chg
Orthobiologics
$33.8
$30.7
$3.1
10.1%
9mo 19
9mo 18
$ Chg
% Chg
Orthobiologics
$107.3
$94.8
$12.5
13.1%
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Copy to clipboard 
